Cover Image
市場調查報告書

多發性骨髓瘤治療藥的全球市場及開發平台分析 (2015年)

Global Multiple Myeloma Drug Market & Pipeline Insight 2015

出版商 KuicK Research 商品編碼 330363
出版日期 內容資訊 英文 415 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
多發性骨髓瘤治療藥的全球市場及開發平台分析 (2015年) Global Multiple Myeloma Drug Market & Pipeline Insight 2015
出版日期: 2015年05月14日 內容資訊: 英文 415 Pages
簡介

全球各地多發性骨髓瘤的患者數增加,不過,還沒有有效的治療藥開發、上市。目前化療是最有效的治療方法,不過,幹細胞移植和基因改造型蛋白質的有效利用也進行討論。今後,隨藥物開發的發展,候補藥開發平台也將強化,預期市場也將擴大。

本報告提供全球各國多發性骨髓瘤治療藥市場趨勢,及開發平台產品的開發情形相關分析、多發性骨髓瘤治療藥的特性和作用機制、整體市場結構、趨勢、開發中產品的目前開發情形、產品單位 (共40個產品) 及各臨床實驗階段的詳細的開發情形、已上市產品 (共9個產品) 銷售情形、今後的市場方向性的資訊,為您概述為以下內容。

第1章 多發性骨髓瘤的概要

第2章 多發性骨髓瘤治療藥的作用機制

第3章 全球多發性骨髓瘤治療藥市場分析

  • 目前市場方案
  • 多發性骨髓瘤的治療藥的臨床實驗平台概要

第4章 全球多發性骨髓瘤治療藥市場動態

  • 有正面作用的市場參數
  • 商業化的課題

第5章 全球多發性骨髓瘤治療藥市場未來展望

第6章 全球多發性骨髓瘤治療藥臨床上的考察:各企業、各適應症、各Phase

  • 研究階段
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第三階段
  • 認證前

第7章 已上市的多發性骨髓瘤治療藥臨床上的考察

  • Bendamustine (Innomustine® Levact®, Treanda® & Treakisym)®
  • Bortezomib (Velcade)®
  • Carfilzomib (Kyprolis)®
  • Doxorubicin Liposomal - ALZA
  • Interferon Alpha-2b (Intron® A)
  • Lenalid(Ladevina® & Revlimid)®
  • Pomalidomide (Imnovid® & Pomalyst)®
  • Thalidomide (Thaled®, Thalidomide Celgene™ & Thalomid)®
  • Zoledronic Acid (Zometa)®

第8章 臨床實驗中止、延期的,臨床實驗平台上的多發性骨髓瘤治療藥

  • 沒有開發報告
  • 臨床實驗中止
  • 臨床實驗延期

第9章 競爭環境

  • AbbVie
  • Altor BioScience
  • Astellas Pharma
  • Astex Pharmaceuticals
  • Benovus Bio
  • Biogen Idec
  • Bristol-Myers Squibb
  • Celegen Pharmaceuticals
  • Cleave Biosciences
  • Genmab
  • Novartis
  • Onyx Pharmaceuticals
  • Pfizer
  • Millennium Pharmaceuticals
  • Vaxil Biotherapeutics

圖表一覽

目錄

Multiple myeloma incidences are increasing across the globe and presently available therapeutics are unable to offer effective clinical benefits. Multiple myeloma chemotherapeutics shows modest pharmacological efficacy due to which necessity for better options are required. Surgery and radiation are equally ineffective and they are not viable for most of the cases. Pharmaceutical companies have identified this scenario due to which they are investing more funds in research and development segment. As a result, investigators would be able to screen more lead molecules for their safety and efficacy in multiple myeloma. Innovative modalities are being studied in clinical trial and they are expected to yield significant results thereby surpassing the issues related with presently available modalities in coming years.

In past few decades several methods for treatment of multiple myeloma has been developed by investigators. Surgery could be performed for transplanting bone marrow from healthy donor. Radiation therapy has modest effect because myeloma cells are spread throughout the body which means higher dosage are required. Chemotherapeutics have been used successfully in past few decades for multiple myeloma treatment. New modalities are being tried by investigators to decrease its morbidity and mortality rates. They are also expected to have lesser side effects and would be able to increase average survival rates. Several innovative multiple myeloma therapeutics is available in market which offers higher safety and efficacy levels. It is expected that new innovative therapeutics would be able to offer better pharmacological benefit to patients and generate significant revenues in coming years.

Stem cell transplant has been suggested by investigators as an effective way to treat multiple myeloma. These cells have capability to differentiate according to the environment in which they have been place. External cues can also be used to transform them into desired type before implanting in the body. Some researchers have proposed the use of recombinant proteins to be implanted in the bone marrow which will prevent the proliferation of multiple myeloma. More time is required to develop and refine this technology which could potentially eliminate multiple myeloma from the body. Such technologies are still under different phases of development and they are expected to take some time before entering in global market. These modalities are expected to change the way multiple myeloma is treated but lots of progress has yet to be made by investigators.

Monoclonal antibodies (mAbs) have been successfully used for the several malignancies due to their superior therapeutic efficacy and high specificity. Targeted mAbs have the ability to bind to specific cells due to which minimized side effects are observed in cancer patients. Investigators are also trying to develop targeted mAbs for treating multiple myeloma which would be offer better therapeutic effects. New modalities like cancer vaccines are also under investigation for studying their pharmacological efficacy. Vaccines for multiple myeloma are under investigation and they are expected to overcome relapse because they activates the patient's immune system. Important part of developing such vaccines is to carefully choose the correct candidate for long-term efficacy. They are also at different stages of clinical trials and strong clinical data is required before their marketing approval in coming years.

Several new developments are expected to take place in field of multiple myeloma segments in coming years. Technological advancements along with rising funding levels is expected to increase the rate of innovations for the development of multiple myeloma drug. As a result, their pipeline is expected to become strong and more clinical trials across the globe are expected to be instigated. Positive outcomes are expected from these clinical trials due to which volume of multiple myeloma therapeutics is going to increase. Simultaneously, there sales are also expected to increase due to profit erosion of presently available therapeutics. In this way, newly introduced multiple myeloma therapeutics are expected to increase several folds in coming years. Besides this, more patients are willing to pay for such therapeutics which can increase their disease free progression.

“Global Multiple Myeloma Drug Market & Pipeline Insight 2015” Report Highlight:

  • Global Multiple Myeloma Drug Market Analysis
  • Global Multiple Myeloma Drug Clinical Insight by Company, Indication & Phase
  • Marketed Multiple Myeloma Drugs Clinical Insight
  • Mechanism of Multiple Myeloma Drug
  • Global Multiple Myeloma Drug Clinical Pipeline: 164 Drugs
  • Majority Multiple Myeloma Drugs in Phase-II Trials: 40
  • Marketed Multiple Myeloma Drugs: 9

Table of Contents

1. Introduction to Multiple Myeloma

2. Mechanism of Multiple Myeloma Drug

3. Global Multiple Myeloma Drug Market Analysis

  • 3.1. Current Market Scenario
  • 3.2. Multiple Myeloma Drug Clinical Pipeline Overview

4. Global Multiple Myeloma Drug Market Dynamics

  • 4.1. Favorable Market Parameters
  • 4.2. Commercialization Challenges

5. Global Multiple Myeloma Drug Market Future Prospects

6. Global Multiple Myeloma Drug Clinical Insight by Company, Indication & Phase

  • 6.1. Research
  • 6.2. Preclinical
  • 6.3. Clinical
  • 6.4. Phase-I
  • 6.5. Phase-I/II
  • 6.6. Phase-II
  • 6.7. Phase-III
  • 6.8. Preregistration

7. Marketed Multiple Myeloma Drugs Clinical Insight

  • 7.1. Bendamustine (Innomustine® Levact®, Treanda® & Treakisym®)
  • 7.2. Bortezomib (Velcade®)
  • 7.3. Carfilzomib (Kyprolis®)
  • 7.4. Doxorubicin Liposomal - ALZA
  • 7.5. Interferon Alpha-2b (Intron® A)
  • 7.6. Lenalidomide (Ladevina® & Revlimid®)
  • 7.7. Pomalidomide (Imnovid® & Pomalyst®)
  • 7.8. Thalidomide (Thaled®, Thalidomide Celgene™ & Thalomid®)
  • 7.9. Zoledronic Acid (Zometa®)

8. Discontinued & Suspended Multiple Myeloma Drugs in Clinical Pipeline

  • 8.1. No Development Reported
  • 8.2. Discontinued
  • 8.3. Suspended

9. Competitive Landscape

  • 9.1. AbbVie
  • 9.2. Altor BioScience
  • 9.3. Astellas Pharma
  • 9.4. Astex Pharmaceuticals
  • 9.5. Benovus Bio
  • 9.6. Biogen Idec
  • 9.7. Bristol-Myers Squibb
  • 9.8. Celegen Pharmaceuticals
  • 9.9. Cleave Biosciences
  • 9.10. Genmab
  • 9.11. Novartis
  • 9.12. Onyx Pharmaceuticals
  • 9.13. Pfizer
  • 9.14. Millennium Pharmaceuticals
  • 9.15. Vaxil Biotherapeutics

List of Figures

  • Figure 1-1: Type of Blood Cancer
  • Figure 1-2: Development of Multiple Myeloma in Body
  • Figure 1-3: Causes of Multiple Myeloma
  • Figure 1-4: Symptoms of Multiple Myeloma
  • Figure 2-1: Diagnosis of Multiple Myeloma
  • Figure 2-2: Stages of Multiple Myeloma
  • Figure 2-3: Treatments Available for Multiple Myeloma
  • Figure 2-4: Mechanism of Doxorubicin
  • Figure 2-5: Mechanism of MAGE-A3 Vaccine
  • Figure 2-6: Mechanism of Carfilzomib
  • Figure 3-1: Global Multiple Myeloma Drug Market Size (US$ Billion), 2015-2019
  • Figure 3-2: Multiple Myeloma Drug Pipeline by Phase (%), 2015
  • Figure 3-3: Multiple Myeloma Drug Pipeline by Phase (Number), 2015
  • Figure 3-4: No Development Reported in Multiple Myeloma Drug Pipeline by Phase (%), 2015
  • Figure 3-5: No Development Reported in Multiple Myeloma Drug Pipeline by Phase (Number), 2015
  • Figure 3-6: Discontinued Multiple Myeloma Drug Pipeline by Phase (%), 2015
  • Figure 3-7: Discontinued Multiple Myeloma Drug Pipeline by Phase (Number), 2015
  • Figure 3-8: Suspended Multiple Myeloma Drug Pipeline by Phase (%), 2015
  • Figure 3-9: Suspended Multiple Myeloma Drug Pipeline by Phase (Number), 2015
  • Figure 4-1: Global Multiple Myeloma Drug Market Favorable Parameters
  • Figure 4-2: Global Multiple Myeloma Drug Commercialization Challenges
  • Figure 9-1: Altor BioScience Clincal Pipeline
  • Figure 9-2: Astex Pharmaceuticals Clincal Pipeline
  • Figure 9-3: Benovus Bio Clincal Pipeline
  • Figure 9-4: Genmab Clincal Pipeline
  • Figure 9-5: Onyx Pharmaceuticals Clinical Pipeline
Back to Top